GLYC Glycomimetics Inc

Price (delayed)

$0.29

Market cap

$18.69M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.58

Enterprise value

-$11.96M

GlycoMimetics is a biotechnology company with a focus in hematology-oncology and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate ...

Highlights
The company's EPS rose by 25% YoY
The debt has declined by 22% since the previous quarter and by 3.2% year-on-year
Glycomimetics's revenue has plunged by 87% YoY
The gross profit has dropped by 87% year-on-year

Key stats

What are the main financial stats of GLYC
Market
Shares outstanding
64.46M
Market cap
$18.69M
Enterprise value
-$11.96M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.65
Price to sales (P/S)
1,869.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-1,195.6
Earnings
Revenue
$10,000
EBIT
-$37.28M
EBITDA
-$36.35M
Free cash flow
-$33.81M
Per share
EPS
-$0.58
Free cash flow per share
-$0.52
Book value per share
$0.45
Revenue per share
$0
TBVPS
$0.53
Balance sheet
Total assets
$34.2M
Total liabilities
$5.29M
Debt
$630,827
Equity
$28.91M
Working capital
$27.97M
Liquidity
Debt to equity
0.02
Current ratio
6.28
Quick ratio
5.91
Net debt/EBITDA
0.84
Margins
EBITDA margin
-363,459.7%
Gross margin
100%
Net margin
-372,767.4%
Operating margin
-394,493%
Efficiency
Return on assets
-76.6%
Return on equity
-88.4%
Return on invested capital
N/A
Return on capital employed
-128.9%
Return on sales
-372,767.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GLYC stock price

How has the Glycomimetics stock price performed over time
Intraday
0%
1 week
7.41%
1 month
11.54%
1 year
-82.84%
YTD
-87.71%
QTD
3.57%

Financial performance

How have Glycomimetics's revenue and profit performed over time
Revenue
$10,000
Gross profit
$10,000
Operating income
-$39.45M
Net income
-$37.28M
Gross margin
100%
Net margin
-372,767.4%
Glycomimetics's revenue has plunged by 87% YoY
The gross profit has dropped by 87% year-on-year
Glycomimetics's net income has increased by 12% YoY
Glycomimetics's operating income has increased by 10% YoY

Growth

What is Glycomimetics's growth rate over time

Valuation

What is Glycomimetics stock price valuation
P/E
N/A
P/B
0.65
P/S
1,869.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-1,195.6
The company's EPS rose by 25% YoY
GLYC's price to book (P/B) is 82% lower than its last 4 quarters average of 3.7 and 62% lower than its 5-year quarterly average of 1.7
Glycomimetics's equity has plunged by 54% YoY and by 25% from the previous quarter
Glycomimetics's revenue has plunged by 87% YoY

Efficiency

How efficient is Glycomimetics business performance
The ROE has contracted by 21% from the previous quarter and by 9% YoY
Glycomimetics's return on assets has decreased by 19% QoQ and by 9% YoY

Dividends

What is GLYC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GLYC.

Financial health

How did Glycomimetics financials performed over time
The total assets has plunged by 50% YoY and by 25% from the previous quarter
GLYC's quick ratio is down by 39% YoY and by 3.3% QoQ
The debt is 98% smaller than the equity
GLYC's debt to equity has soared by 100% year-on-year
Glycomimetics's equity has plunged by 54% YoY and by 25% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.